Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Renal Cell 29Carcinoma, Hepatocellular 16Prostatic Neoplasms 12Neoplasm Metastasis 11Carcinoma, Non-Small-Cell Lung 9Neoplasms 8Sarcoma 7Osteosarcoma 6Neuroendocrine Tumors 6Brain Neoplasms 6Urinary Bladder Neoplasms 5Kidney Neoplasms 5Carcinoma, Transitional Cell 5Breast Neoplasms 5Sarcoma, Ewing 4Melanoma 4Lung Neoplasms 4Recurrence 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Clear-cell metastatic renal cell carcinoma 3Carcinoid Tumor 3Adrenocortical Carcinoma 3Adenocarcinoma 3Wilms Tumor 2Uterine Cervical Neoplasms 2Urethral Neoplasms 2Thyroid Neoplasms 2Thyroid Diseases 2Thyroid Cancer, Papillary 2

Interventions

Specimen Handling 3Nivolumab 3olaparib 2durvalumab 2Magnetic Resonance Spectroscopy 2Ipilimumab 2CTLA-4 Antigen 2temsirolimus 1serabelisib 1sapanisertib 1rucaparib 1copanlisib 1ceralasertib 1cediranib 1capivasertib 1cabozantinib 1Paclitaxel 1Immunoglobulin G 1Fluid Therapy 1Disulfides 1Carboplatin 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Endometrioid × cabozantinib × Clear all
NCT01935934 2025-10-01

Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Completed
102 enrolled 14 charts

Carcinoma, Endometrioid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡